As NICE begins to incorporate health equity into drug reimbursement decisions, forward-looking pharmaceutical companies have a chance to lead – aligning innovation with access drivers and g
In the feature ‘Successfully navigating the complexity of market access across Europe to improve health equity’, originally published in the European Biopharmaceutical Review, EVERSANA Gene